Novavax, Inc., a biotechnology company dedicated to developing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Ltd., a biotechnology company in South Korea, have submitted a Biologics License Application (BLA) for Novavax’ COVID-19 vaccine to South Korea’s Ministry of Food and Drug Safety (MFDS). NVX-CoV2373, Novavax’ recombinant nanoparticle COVID-19 vaccine with Matrix-M adjuvant, is the first protein-based COVID-19 vaccine to be submitted for...